RVMD Q3 2021 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-91.3% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$53M-4828.6% margin

Net Income

-$53M-4808.4% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

-87.3%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$735M

Total Liabilities

$97M

Stockholders' Equity

$638M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$13M	-91.3%
Gross Profit	$1M	$13M	-91.3%
Operating Income	-$53M	-$28M	-93.0%
Net Income	-$53M	-$27M	-94.5%

Revenue Segments

Collaboration Revenue

$1M100%